Product Information
Ascorbigen is the most prevalent of several Dietary Indoles shown to have significant physiological activity [13] and may be the essential component making Dietary Indoles beneficial [14]. Ascorbigen is a skin-permeable form of Vitamin C formed from Indole-3-Carbinol in the presence of aqueous ascorbic acid.
Ascorbigen is produced naturally in cruciferous vegetable juices when cell walls are broken through chopping, chewing, or juicing* [15]. First identified in 1935 [16], Ascorbigen was isolated from Savoy cabbage juice in 1957 [17]. Ascorbigen may exhibit synergy with Indole-3-Carbinol [18-19].
Ascorbigen helps the body prevent absorption of toxins through the small and large intestines [1] and exhibits provitamin [2-6], immunostimulatory [3-6], and skin conditioning properties [7]. Ascorbigen’s usefulness is largely attributed to its ability to support the body’s natural metabolism of hormones and promote good estrogen (2-Hydroxyestrone) [9].
Adults 200 to 400 mg per day. Children may take up to 1/2 adult dosage.
Ascorbigen is the most stable of commercially available Dietary Indoles. It requires neither refriger- ation nor protection from light. Degradation will occur at temperatures in excess of 50ºC. Trace amounts of more reactive Dietary Indoles contribute to product color.
Dietary Indole CAS Registry Number [8075-98-7]
Ascorbigen is a dietary supplement under provisions of US Dietary Supplement Health and Education Act of 1994 (DSHEA).
Amounts in excess of recommended dosages may cause diarrhea.
1. McDanell, R. et al. 1987 Food and Chemical Toxicology 25: 363-368.
2. Bukin, Y.V. et al. 1987 Khimi IA 13: 539-545.
3. Mukhanov, V.I. et al. 1984 Soviet Journal of Bioorganic Chemistry 10: 544-559.
4. Plikhtyak, I.L. et al. 1988 Khim. Getcrotsikl. Sosdin.131-132
5. Efimox, S.A., 1989 Antibiot. Khimioter 34: 125-129.
6. Anonymous, 1978 Analysis and Research (Japan)
16: 546-550.
7. Fukushima, S., Toyoda, H., 1987 Japan Kokai Tokyo Koho Japanese patent. 62/155204 A2 [87/155204] July 10.
8. Andrus, G.M., Arffman, K., 1999 United States Patent. 5895787, April 20.
9. Michnovicz, J. J.; Bradlow, H. L. 1991 Nutr. Cancer
16: 59-66. Michnovicz, J. J.; Bradlow, H. L. 1990, Natl. Can. Inst. 82: 947-949
10. Sepkovic, D. et al. 1994 Steroids 59: 318-323.
11. Bell, M.C. et al. 2000, Gynecologic Oncology 78: 123-129.
12. Newfield, L. et al. 1993, Anticancer Research 13: 337-342.
13. Loub, W.E., Wattenberg, L.W., Davis, D.W., 1975 J. Nat. Can. Inst. 54: 985-988.
14. Preobrazhenskaya, M. N. andKorolev, A.M. 1992 Journal of the National Cancer Institute 84: 15, 1210-1211
15. Zeligs, M.A., 1998 Journal of Medicinal Food 1:2, 67-82
16. Ahmad, B., 1935 Biochemistry Journal 29: 275
17. Prochazka, Z. et al. Collection of Czechoslovakian 1957 Chemical Communications 22: 333, 654
18. Chinoy, N.J., 1977 Journal of Animal Morphology and Physiology 24: 173-185.
19. Kahatriya, A.M., 1977 Journal of Animal Morphology and Physiology 24: 379-386.